Skip to content
Open access

Plasma Proteomic Signatures for Early Risk Stratification Across Cardiovascular‐Kidney‐Metabolic Stages 0–2

Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11901 - 11914 · 0 citations · 33 references
Medicine

Abstract

Cardiovascular‐kidney‐metabolic (CKM) stages 0–2 represent a potentially modifiable period before overt cardiovascular complications, yet molecular markers that identify individuals at higher downstream risk remain insufficiently defined. We investigated whether plasma proteomic signatures could characterize early CKM‐related molecular risk and improve prediction of incident cardiovascular, kidney and mortality outcomes.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.